Radiation, Hormone Therapy Extend Survival in Advanced PC, Phase 3 Trial Shows

Radiation, Hormone Therapy Extend Survival in Advanced PC, Phase 3 Trial Shows
A combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) is better at delaying disease progression and extending survival of patients with locally advanced prostate cancer than ADT alone, a Phase 3 trial shows. The study, "Long‐term androgen deprivation, with or without radiotherapy, in locally‐advanced prostate cancer: updated results from a phase III randomized trial," was published in BJU International. Previous studies have shown that EBRT, the most common type of radiation therapy, together with ADT, a hormone therapy that aims to slow disease progression by reducing levels of male hormones, led to significant improvements in patients' survival compared to EBRT alone. More recently, the Phase 3 clinical trials NCT00002633 and ISRCTN01534787, plus a third trial, have shown that a combination therapy of ADT and EBRT led to better clinical outcomes compared to ADT alone in patients with locally advanced prostate cancer — that which has spread outs
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *